Cue Biopharma Stock Widgets and Gadgets
| CUE Stock | USD 1.89 0.02 1.07% |
| Intraday Equity Chart Quick Equity Feed Equity Search Quote Ticker Widgets Data Sheet |
Live Stock Ticker Example
- CUE Cue Biopharma
- Latest FDA advises against using Cue Health COVID-19 tests, sends warning letter
- CUE 1.89 0.02
- Low 1.74
- High 1.94
- Volume 185.3 K
- Alpha 0.0222
- Beta -0.31
- Return On Equity -1.17
- Return On Asset -0.47
- Operating Margin (7.38) %
- Current Valuation 63.66 M
- Shares Outstanding 48.64 M
- Shares Owned By Insiders 0.67 %
- Shares Owned By Institutions 33.91 %
- Number Of Shares Shorted 4.96 M
- Price To Earning (2.17) X
- Price To Book 2.28 X
- Price To Sales 15.51 X
- Revenue 5.49 M
- Gross Profit 1.25 M
- EBITDA (48.56 M)
- Net Income (50.73 M)
- Cash And Equivalents 66.13 M
- Cash Per Share 1.87 X
- Total Debt 14.7 M
- Debt To Equity 0.33 %
- Current Ratio 8.29 X
- Book Value Per Share 0.62 X
- Cash Flow From Operations (39.96 M)
- Short Ratio 15.88 X
- Earnings Per Share (1.07) X
- Target Price 9.4
- Number Of Employees 53
- Beta 1.97
- Market Capitalization 91.69 M
- Total Asset 61.53 M
- Retained Earnings (301.19 M)
- Working Capital 34.37 M
- Current Asset 42.21 M
- Current Liabilities 3.38 M
- Net Asset 61.53 M
- Accumulation Distribution 19105.98
- Daily Balance Of Power 0.1
- Rate Of Daily Change 1.01
- Day Median Price 1.84
- Day Typical Price 1.86
- Price Action Indicator 0.06
- Period Momentum Indicator 0.02
- Relative Strength Index 51.34
Market Snapshot Widget Example
DAX Index Germany | 18,727 0.22 | |
Taiwan Weighted Taiwan | 21,237 0.16 | |
PSI 20 Stock Portugal | 6,906 0.04 | |
CROBEX Croatia | 2,828 0.13 | |
Budapest SE Hungary | 67,866 0.33 | |
IDX 30 Jakarta Indonesia | 448.48 2.02 | |
ISEQ 20 Price Ireland | 1,667 0.15 | |
NYSE Comp USA | 18,338 0.01 | |
Tel Aviv 35 Israel | 1,974 0.31 | |
Coreshares Index Tracker South Afric | 1,063 1.85 | |
IPC MEXICO Mexico | 56,761 1.43 | |
KL Technology Malaysia | 72.82 0.55 | |
IBEX 35 Index Spain | 11,335 0.04 | |
SP Merval Argentina | 1,000,000 0.00 | |
Austrian Traded Index Austria | 3,775 0.30 | |
SPASX Dividend Opportunities Australia | 1,684 0.08 | |
HNX 30 Vietnam | 533.02 0.54 | |
Bucharest BET-NG Romania | 1,239 1.07 | |
AMS Small Cap Netherlands | 1,225 0.49 | |
Oslo Exchange Mutual Norway | 1,373 0.46 | |
BEL Small Belgium | 9,118 0.02 | |
RTSI Index Russia | 1,200 0.34 | |
Basic Materials Brazil | 5,721 0.91 | |
Swiss Leader Price Switzerland | 1,955 0.21 | |
Fondo Mutuo ETF Chile | 1,440 0.03 | |
Athens General Comp Greece | 1,496 0.43 | |
Stock Exchange Of Thailand | 1,371 0.57 | |
PX Prague Stock Czech Repub | 1,568 0.40 | |
THE PHILIPPINE STOCK Philippines | 6,634 0.74 | |
WIG 30 Poland | 3,223 0.99 | |
BIST Electricity Turkey | 605.52 1.4 |
Investing Ideas
In addition to having Cue Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Thematic Opportunities
Explore Investment Opportunities
Compare Cue Biopharma
Compare Cue Biopharma To Peers
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cue Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Complementary Tools for Cue Stock analysis
When running Cue Biopharma's price analysis, check to measure Cue Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cue Biopharma is operating at the current time. Most of Cue Biopharma's value examination focuses on studying past and present price action to predict the probability of Cue Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cue Biopharma's price. Additionally, you may evaluate how the addition of Cue Biopharma to your portfolios can decrease your overall portfolio volatility.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |
Is Cue Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cue Biopharma. If investors know Cue will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cue Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.07) | Revenue Per Share 0.149 | Quarterly Revenue Growth 8.182 | Return On Assets (0.47) | Return On Equity (1.18) |
The market value of Cue Biopharma is measured differently than its book value, which is the value of Cue that is recorded on the company's balance sheet. Investors also form their own opinion of Cue Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Cue Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cue Biopharma's market value can be influenced by many factors that don't directly affect Cue Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cue Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cue Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cue Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.